.webp&w=384&q=75){kind=logo}
Loading, please wait...
Loading, please wait...
The FLAME trial addressed a practical COPD question: for patients at risk of exacerbations, is a long-acting beta2-agonist plus long-acting muscarinic antagonist better than an inhaled corticosteroid/LABA combination? In this 52-week randomized trial, once-daily indacaterol–glycopyrronium was compared with salmeterol–fluticasone in more than 3,300 patients with COPD and a history of exacerbation. The dual-bronchodilator regimen was noninferior and showed a lower overall exacerbation rate than the LABA–ICS regimen. Moderate-to-severe exacerbations were also less frequent with indacaterol–glycopyrronium, and pneumonia occurred less often in that group. The clinically useful message is not that ICS has no role in COPD, but that bronchodilation should remain central to maintenance treatment and that routine LABA–ICS is not necessarily the best starting strategy for every patient. In practice, treatment should be individualized around exacerbation history, symptom burden, blood eosinophils, and coexisting asthma features. The study is especially relevant to the conference focus on moving beyond spirometry alone when phenotyping COPD and making the ICS decision.
Read summarized clinical updates, watch expert medical content, and earn CME certifications right from your smartphone.
Open your smartphone camera to scan and install.
The FLAME trial addressed a practical COPD question: for patients at risk of exacerbations, is a long-acting beta2-agonist plus long-acting muscarinic antagonist better than an inhaled corticosteroid/LABA combination? In this 52-week randomized trial, once-daily indacaterol–glycopyrronium was compared with salmeterol–fluticasone in more than 3,300 patients with COPD and a history of exacerbation. The dual-bronchodilator regimen was noninferior and showed a lower overall exacerbation rate than the LABA–ICS regimen. Moderate-to-severe exacerbations were also less frequent with indacaterol–glycopyrronium, and pneumonia occurred less often in that group. The clinically useful message is not that ICS has no role in COPD, but that bronchodilation should remain central to maintenance treatment and that routine LABA–ICS is not necessarily the best starting strategy for every patient. In practice, treatment should be individualized around exacerbation history, symptom burden, blood eosinophils, and coexisting asthma features. The study is especially relevant to the conference focus on moving beyond spirometry alone when phenotyping COPD and making the ICS decision.
Today
The phase 3 ACACIA-HCM trial reveals that aficamten improves cardiac structure, diastolic relaxation, functional capacity, and symptom burden in symptomatic nonobstructive hypertrophic cardiomyopathy, marking a major milestone in targeted myosin inhibition.
6 days back
A clinical study shows that automated breast ultrasound paired with artificial intelligence accurately classifies BIRADS 3-4 lesions, reaching 95% sensitivity and 79% specificity. This diagnostic advance promises to reduce unnecessary core needle biopsies and refine clinical workflows in breast imaging.
3 weeks back
Researchers have engineered freestanding hierarchical-porous BCZT thin films that resist cracking and enhance ultrasonic energy harvesting in soft tissue. Achieving high piezoelectric output and acoustic matching, this lead-free material offers transformative potential for implantable bioelectronics.
6 days back
A novel pathology-adaptive surface engineering strategy uses functionalized plasma polymer coatings to selectively modulate AGE adsorption, reducing oxidative stress and restoring bone formation in diabetic and aging microenvironments.
3 weeks back
A breakthrough study identifies the Klotho/PKCα/CUX1/SPARC/TGFβ-RII axis as a critical driver of podocyte mitochondrial injury and ferroptosis in diabetic kidney disease, unveiling promising molecular targets to halt renal disease progression.
6 days back
